RxDoctor Payments Data

Michael Davis, MD

Family Medicine · Metairie, LANPI 1629061726

Payments from drug & device makers

$972in general payments, 2019–2025

Across 23 payments — averaging $42.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$328
  • Inari Medical, Inc.$252
  • Cardiovascular Systems Inc.$238
  • Johnson & Johnson$60
  • Abbott$24
  • Pfizer$21
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$972 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,571
Medicare patients
146
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$133,090
JardianceEmpagliflozin98$103,635
OzempicSemaglutide78$101,504
TrulicityDulaglutide22$34,725
MounjaroTirzepatide25$27,361
JanuviaSitagliptin Phosphate15$20,497
TradjentaLinagliptin12$18,127
EntrestoSacubitril/Valsartan15$16,507
CreonLipase/Protease/Amylase13$14,693
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,232
Spiriva HandihalerTiotropium Bromide17$8,622
Fluticasone-SalmeterolFluticasone Propion/Salmeterol46$8,510
Rosuvastatin Calcium508$6,055
Atorvastatin Calcium540$5,382
Valsartan190$5,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$133,090190 claims
GSKTrelegy Ellipta, Breo Ellipta$12$18,11026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →